Want to see PCVX full AI Analyst Report?
PCVX Stock Chart & Stats
$62.35
-$2.14(-2.45%)
At close: 4:00 PM EST
$62.35
-$2.14(-2.45%)
Day’s Range― - ―
52-Week Range$29.08 - $65.00
Previous CloseN/A
Volume105.48K
Average Volume (3M)1.64M
Market Cap
$8.12B
Enterprise Value$6.49K
Total Cash (Recent Filing)$1.74B
Total Debt (Recent Filing)$116.30M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 12, 2026EPS Estimate
-2.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.89
Shares Outstanding144,397,670
10 Day Avg. Volume980,720
30 Day Avg. Volume1,638,305
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-9.38
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$116.00Price Target Upside86.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-8.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA sizable equity base and low debt provide durable financial flexibility to fund multi-year clinical programs, negotiate partnerships, and weather trial delays without immediate revenue. This reduces short-term insolvency risk and supports continued R&D investment over the next 2–6 months.
Platform & Target MarketA differentiated carrier-sparing polysaccharide platform aimed at broader pneumococcal serotype coverage addresses a structural unmet need in vaccines. If clinical data validate breadth and manufacturability, the platform supports durable competitive positioning and multiple future product or licensing opportunities.
Governance & Strategic OversightAddition of an experienced industry director and continuity from shareholder re-elections strengthen strategic oversight, manufacturing and supply expertise. Better governance and board expertise improve execution odds on complex clinical and commercialization planning over the medium term.
Bears Say
No Commercial RevenueAbsence of product revenue means the firm must rely on financing or partnerships to sustain operations. Without commercial cash flows, ongoing R&D and operating losses will continue to deplete capital, making long-term planning dependent on successful trials or external funding.
Accelerating Losses & Scale Of DeficitsRapidly widening operating losses indicate rising development scale and expense commitments. Over a multi-month horizon this increases financing needs, heightens dilution risk, and constrains optionality for new programs unless offset by milestone partnerships or successful clinical readouts.
High Cash Burn & Negative Free Cash FlowConsistent and deep negative operating and free cash flow erodes runway and forces recurring capital raises or asset monetization. This structural cash consumption limits strategic flexibility, can delay programs if funding tightens, and raises the probability of disruptive financing over months.
Vaxcyte News
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $29.08 and its highest was $65.00 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $8.12B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 23 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on May 06, 2026. The company reported -$2.3 earnings per share for the quarter, missing the consensus estimate of -$1.778 by -$0.522.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -2.06.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 144,397,670 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$2.3 in its last earnings report, missing expectations of -$1.778. Following the earnings report the stock price went down -9.842%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in PCVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxcyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$116.00 (86.05% Upside)
$116.00 (86.05% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.38%
12-Months-Change
Fundamentals
Return on Equity
-32.51%
Trailing 12-Months
Asset Growth
-0.88%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
PCVX Stock 12 Month Forecast
Average Price Target
$116.00
▲(86.05% Upside)
Technical Analysis
Ownership Overview
0.76% Insiders
39.37% Mutual Funds
0.12% Other Institutional Investors
41.94% Public Companies and
Individual Investors